Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Larvae 'could replace use of adult fish in pain research'
zebrafish
The team recommend that larval zebrafish could be used as a model for the study of pain.

Scientists find larval zebrafish respond to pain and pain relief

Liverpool researchers say larval zebrafish could be used as an alternative model for the study of pain, sparing the many adult zebrafish that are currently used in toxicity tests.

The University of Liverpool's Dr Lynne Sneddon, who debunked the theory that fish cannot feel pain, was uncomfortable about the increasing use of adult fish in pain research, and decided to lead a study on replacing them with larvae that are just a matter of days old.

Researchers exposed five-day post-fertilisation zebrafish embryos to dilute concentrations of acetic acid and citric acid, which are known to irritate adult fish.

Using software to track their motions, the team found that in the most concentrated solutions of acetic acid, and all concentrations of citric acid, the minute fish swam harder and farther, possibly to escape the uncomfortable feeling. However, the larvae became less active in the two most dilute solutions of acetic acid.

When researchers administered pain relief to the disturbed larvae (in the form of aspirin, morphine and lidocaine) the discomfort appeared to ease and their behaviour returned to normal.

As a result the team recommend that larval zebrafish could be used as a model for the study of pain. Their full findings were published in the Journal of Experimental Biology. 

Image by Oregon State University (CC BY-SA 2.0)

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
BVA urges 'continued vigilance' over bluetongue

The British Veterinary Association (BVA) has urged vigilance following a concerning rise in Bluetongue (BTV) cases in sheep and cattle.

In a recent statement, the BVA noted that members are reporting more severe clinical signs and higher mortality rates than in previous years.

'We know that farm vets are working hard to support farmers and animals affected by this outbreak, during what is an extremely difficult time for all involved,' they stated. 'Continued vigilance to identify disease early is vital and vaccination remains the best way of protecting animals from this disease.'